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A B S T R A C T
Background: Chagas disease (CD), is a parasitic disease endemic in Latin America. Presentation in non-endemic
areas is either in the asymptomatic indeterminate phase or the chronic phase with cardiac and/or gastro-
intestinal complications.
Methods: The Hospital for Tropical Diseases (HTD) based in central London, provides tertiary care for the
management of CD. We reviewed all cases managed at this centre between 1995 and 2018.
Results: Sixty patients with serologically proven CD were identified. Most were female (70%), with a median age
at diagnosis of 41 years. Three quarters of the patients were originally from Bolivia. 62% of all patients were
referred to the HTD by their GP. Nearly half of the patients were asymptomatic (47%). Twelve patients had signs
of cardiac involvement secondary to CD. Evidence of gastrointestinal damage was established in three patients.
Treatment was provided at HTD for 31 patients (47%). Most patients (29) received benznidazole, five of them
did not tolerate the course and were switched to nifurtimox. Of the seven patients receiving this second line
drug, five completed treatment, whilst two interrupted it due to side effects.
Conclusions: Despite the UK health system having all the resources required to diagnose, treat and follow up
cases, there is lack of awareness of CD, such that the vast majority of cases remain undiagnosed and therefore do
not receive treatment. We propose key interventions to improve the detection and management of this condition
in the UK, especially in pregnant women and neonates.
1. Introduction
Chagas disease (CD) was described by the Brazilian physician and
epidemiologist Carlos Chagas in 1909. Caused by the protozoan para-
site Trypanosoma cruzi, (T. cruzi) transmitted by the bite of reduviid
bugs, it is endemic to parts of North, Central and South America. Six to
seven million individuals worldwide are infected [1,2].
In Europe, a non-endemic area, there were estimated to be between
68,000 and 122,000 infected individuals in 2009, with only 4290 di-
agnosed [3,4]. In 2015, the prevalence of Chagas disease in Latin
American migrants living in Europe was estimated at 4.2% [5].
CD has an acute phase, which is amenable to treatment if detected
early. It then enters an indeterminate (asymptomatic phase) for dec-
ades. 30–40% of those infected go on to develop cardiac or gastro-
intestinal complications [1]. The global economic cost of this disease is
around $7 billion a year [6].
CD is primarily a disease of poverty and poor housing. However, T.
cruzi is also transmitted by blood, organ donation, and vertically from
mother to child. International migration patterns and these methods of
potential transmission make vertical, blood-borne and organ-trans-
mitted acquisition of T. cruzi a possibility in non-endemic countries [4].
The reasons for there being a low-detection rate are many-fold:
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i. Lack of awareness among European specialists and general practi-
tioners.
ii. Challenges in screening: lack of systems in place to request the in-
itial serological test in primary health care and budgetary con-
straints.
iii. The affected communities may not access health services [7] or
choose to limit their access to health care in some instances in fear
of their illegal migration status being disclosed.
iv. Delay in diagnosis due to the asymptomatic nature of the chronic
phase of the disease [3].
The Hospital for Tropical Diseases (HTD) London is a secondary and
tertiary referral centre for T. cruzi cases linked with the UK National
Parasitology Reference Laboratory. As a specialist centre, we reviewed
all cases we diagnosed and managed between October 1995 and
November 2018.
2. Materials and methods
Assessment of new patients with Chagas disease. Patients seen in the
HTD clinics for T. cruzi infection may present as i) a self-referral with a
previous diagnosis from their country of origin, ii) a referral from pri-
mary health care, iii) a referral from another speciality or from in-
fectious diseases units elsewhere, following a positive serological test.
At presentation, a detailed travel, family and clinical history is
taken. Patients’ sera are tested first by ELISA. Any ELISA positive sera
are tested by IFAT with titre. Those positive in both tests are considered
confirmed cases. PCR for T. cruzi, an HIV test, chest x-ray, ECG and an
echocardiogram are also offered. In the presence of cardiac or gastro-
intestinal complications, patients may be referred to the appropriate
team for assessment. Antiparasitic treatment may also be offered when
indicated [2].
Asymptomatic patients are reviewed annually with an ECG, T. cruzi
serology (ELISA) and PCR. At 5-yearly follow-up, they are offered a
repeat echocardiogram. Repeat chest x-rays are no longer requested
routinely. Other tests e.g. 24 h Holter ECG monitoring, abdominal x-ray
or specific gastrointestinal investigations are requested if symptoms
warrant.
The initial laboratory diagnosis of chronic CD is made primarily by
serological methods. At HTD, serum samples are screened using a
commercial recombinant antigen-based ELISA assay and, if positive, the
result is confirmed using an in-house indirect fluorescent antibody test
(IFAT) using whole trypomastigotes. At subsequent follow-up appoint-
ments sera are tested by ELISA only [8]. PCR molecular testing is un-
dertaken prior to commencing treatment and in subsequent follow-up
clinic appointments. Treatment options are benznidazole as first line, or
nifurtimox [2]. The treatment regimens in use at the Hospital for Tro-
pical Diseases are benznidazole for 60 days (5 mg/kg/d in 2 divided
doses) or nifurtimox for 60 days, (8 mg/kg/d in 3 divided doses). Full
blood count and liver function tests are checked during treatment at
two weekly intervals.
2.1. Data collection
Patients diagnosed as seropositive for T. cruzi between July 1995
and March 2018 were identified from the HTD Department of Clinical
Parasitology laboratory database and data collected in a questionnaire
designed for the audit. Information was extracted from patient notes
and electronic records. Attempts to collect missing data were made by
contacting patients’ GPs and referring clinicians across the country.
Audit data collected included age, sex, referral pathway, geo-
graphical origin, travel history, family history, clinical history, labora-
tory and radiology results, treatment and follow up. For female pa-
tients, data relating to children and pregnancies were also collated.
The clinical status of CD in seropositive patients was graded as in-
determinate, cardiac, digestive or cardiodigestive according to Kuschnir
(cardiac) [9] and Pinazo-Rezende (digestive) classifications [1,10,11].
3. Results
Between July 1995 and March 2018, 78 patients with positive T.
cruzi serology results were identified, 16 were excluded from the ana-
lysis as they had never been seen at HTD; two patients were excluded as
the serology results were thought to be false positives. The assessment
and management by the HTD of 60 patients with serologically proven
CD is presented below. The distribution of cases seen at HTD during the
period reviewed is represented in Fig. 1.
Although there are more Latin American women (55%) than men
living in England & Wales as a whole [12], this only partly explains our
figures, as in our series, the percentage of patients who were female was
greater, at 70% (n = 42). It points towards a difference in level of
healthcare access by gender in Latin Americans in the UK, but is not
explained by antenatal screening, as although 36/42 (86%) of our fe-
male patients were of child-bearing age, only three were pregnant when
first seen. This is disappointing and may reflect the fact that there is no
systematic antenatal screening programme for Chagas disease in the
UK.
The median age at presentation at the HTD was 41 years (range:
18–67 years). In two cases, the country of origin was not recorded. The
rest of the cohort was originally from CD endemic areas in South
America. Most of patients were originally from Bolivia (45, 75%), fol-
lowed by Brazil (4, 7%), Colombia (3, 5%), and the remaining 8 (15%)
from Argentina, Chile, Ecuador, Uruguay and Venezuela. In the ma-
jority of patients (54, 90%) the country of birth of the patient, country
of exposure and country of origin of patient's mother coincided. One
patient did not know the country of origin of her biological mother as
she was adopted, another patient was born in Uruguay from a Brazilian
mother.
Two thirds of the cohort (40, 67%) were already aware of their CD
diagnosis on arrival in the UK. Just over half of the patients were di-
agnosed in their home countries (31, 52%); followed by those diag-
nosed in Spain (9, 15%). Of the patients diagnosed in the UK (20, 33%),
Abbreviations
CD Chagas Disease
HTD Hospital for Tropical Diseases
T. cruzi Trypanosoma cruzi
Fig. 1. Trend in presentation of CD cases at the Hospital for Tropical Diseases
(1995–2018).
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the trigger for diagnosis was being originally from an endemic area (18,
90%), two patients from endemic areas were identified in specific si-
tuations (one on attending an antenatal clinic and another on screening
for blood donation).
All women diagnosed with CD were older than 18 years when first
presenting at the HTD; most (36/42; 86%) were of child bearing age
(defined as 15–49 years old). Three patients were pregnant when first
seen (3/42; 7%); for five women of child bearing age (5/42; 12%) there
was no record of enquiring about pregnancy, offering or performing a
pregnancy test.
More than half the female CD patients had offspring (26/42; 62%);
testing or offering to test children was only documented for 22 of the 26
mothers with positive CD serology. In 6 cases (6/42; 14%) no in-
formation was available on whether or not the female CD patient had
children.
Information regarding patients' relatives is presented in Table 1.
Excluding one patient who was thought to have acquired the infection
through blood transfusion, the mode of transmission for the rest of the
patients was unclear. Nine patients reported their mother had been
diagnosed with CD. Four patients reported their mother and at least one
of their siblings had been diagnosed with CD making congenital in-
fection a possible route of transmission, though in a region with active
vectorial transmission, that route is also possible in the same household.
The patients accessed HTD through different pathways. Most pa-
tients were referred by their general practitioners (37, 62%), followed
by patients transferred from specialist clinics (17, 28%), and one in ten
patients self-presented (6, 10%). The majority of patients (50, 83%)
were referred for consideration of treatment.
Just under half the patients were asymptomatic on their first visit to
HTD (28, 47%). Among those with symptoms (32, 53%), half 16
(26.7%) reported cardiac symptoms (16/32, 50%) and 11 (18.3%)
gastrointestinal symptoms (11/32, 34%), and five patients reported
symptoms affecting both organ systems (5/32, 16%). However, re-
ported symptoms such as constipation or palpitations may have other
causes and not necessarily be related to Chagas disease. For example,
33% of patients with cardiac symptoms were Kuschnir grade 0 (Table 2)
and 75% of patients with gastrointestinal symptoms were Rezende
grade 0 (Table 3). No chagomas or acute CD presentations were iden-
tified.
HIV testing was not performed systematically for all patients but at
the discretion of the treating physician. There was one case of co-in-
fection in this cohort, but the patient was known to be HIV-positive at
referral.
As per the audit inclusion criteria, patients had a positive ELISA
antibody test for T. cruzi. Thirteen patients did not have an IFAT result
recorded; for those who had a result available, both the median and
mode IFAT titre was 1:160 (range 1:20 [the screening dilution] which is
weakly positive to 1 > 2650 very strongly positive). Of eight PCR
positive patients, seven had IFAT titres of greater than or equal to 1 in
320 and the eighth had a titre of 1 in 160, suggesting that higher IFAT
titres were associated with PCR positivity, indicative of persisting
parasite multiplication. Fifty six patients had a T. cruzi PCR performed.
This test was positive in 8/56 (14%) and equivocal in 2/56 (4%). One of
the patients with an equivocal test at initial diagnosis was retested post-
treatment and was negative, the other patient was lost to follow up.
More than three quarters of patients had a negative PCR (46/56, 82%).
All previously treated patients were negative by PCR on first pre-
sentation to HTD. All positive PCR cases were among untreated patients
and they had higher IFAT titres (1:160 and above). IFAT and PCR po-
sitivity are shown in Fig. 2.
Due to the retrospective nature of the study, the diagnostic tests
were performed at the discretion of the treating physician, no sys-
tematic protocol was followed, but a unified policy for investigation
and case management is now in place.
Routinely, patients would be screened for cardiac abnormalities,
ECG and echocardiogram results were available for most patients (57/
60, 95% and 52/60, 87%). The use of Chest X-ray is decreasing, whilst
24 h ECG tapes have been used more frequently in recent years. A third
of patients with physician-diagnosed cardiac symptoms (7/21) had
normal cardiac tests, whilst there was no correlation between the se-
verity of symptoms reported and Kuschnir grading. Among asympto-
matic patients (4/28, 14%) had incidental findings on ECG or echo-
cardiogram. Over half of the patients (32/60, 53%) had an abdominal
X-ray performed, upper and lower gastrointestinal studies were re-
quested based on symptoms. Results of Kuschnir and Rezende grading
of symptomatic patients are shown in Tables 2 and 3
Seven patients (7/60, 12%) had already been treated for CD when
presenting to HTD, and were considered to be cured. Five patients (5/
60, 8%) were lost to follow up before treatment could be discussed.
Eight patients (8/60, 13%) were considered ineligible for antiparasitic
drug treatment by age criteria, six (6/60, 10%) declined treatment and
three (3/60, 5%) are on the waiting list to be treated. Initially, we were
cautious and limited treatment to younger age groups (younger than 50
years) due to concern about drug toxicity in older patients. We now
consider drug treatment in discussion with patients from any age group,
balancing the potential benefits versus risk of side-effects [13].
Just over half of the cohort (31/60, 52%) received treatment at
HTD. Most patients received benznidazole as first line (29/31, 94%),
more than two thirds (20/29, 69%) reported side effects. The most
common side effect from benznidazole therapy was a skin rash. This
was treated with antihistamines and most patients were able to con-
tinue and complete the course of treatment.
However, five (5/29, 24%) did not complete the course and were
switched to nifurtimox. In addition to those five, two patients were
started directly on nifurtimox. Of the seven patients on nifurtimox, five
(71%) reported side effects, four (57%) completed the course, but the
other three (42.8%) discontinued treatment. Nifurtimox most com-
monly led to gastrointestinal side effects, but one patient developed
high fever and myalgia, severe enough to require hospital admission.
Regarding access to treatment, cost is not a barrier to receiving
antiparasitic drugs for Chagas disease. In the UK National Health
Service, there is no charge for drugs received as an in-patient. As at May
2020, outpatients pay only GBP 9.15 for each drug prescribed so for
example, a whole course of benznidazole would only cost them that
amount. Furthermore, patients may claim exemption from the pre-
scription charge as follows: Under 16, aged 16–18 and in full time
education, aged 60 or over. Pregnant women and those who have had a
baby in the last 12 months. Patients receiving benefits, tax credits, or on
low income.
Two thirds of the patients (40/60; 66%) are still followed up rou-
tinely at HTD. Just over a quarter (16/60; 27%) were lost to follow up;
4 patients were discharged from clinic. The children of 10 women af-
fected by CD were tested and were all negative. No cases of vertical
transmission were identified.
4. Discussion
Due to the changing patterns of migration from Latin America, ei-
ther directly or indirectly via Spain, CD is an increasing and under re-
cognized public health problem in the UK, largely due to the fact that it
is commonly asymptomatic. Funded by the European Union, COHEMI
(COordinating resources to assess and improve HEalth status of
MIgrants from Latin America) looked at health policies to control blood,
Table 1
Infection status in relatives of our Chagas disease patients.
Mother Siblings Other family members
Known Positive 12/60 (20%) 15/60 (25%) 17/60 (28%)
Known Negative 9/60 (15%) 9/60 (15%) 7/60 (12%)
Not known/not recorded 39/60 (65%) 36/60 (60%) 36/60 (60%)
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organ and congenital transmission of CD. The recommendation was
that all countries in Europe should have in place policies to ensure
screening for CD in blood and transplant donation; and for antenatal
and congenital cases; implementation of these policies should be
monitored and regularly evaluated [4].
Basile et al. (2011) estimated that there were between 6111 and
12,201 T. cruzi-infected migrants in the United Kingdom [3]. Although
the UK shows a relatively low number of Latin American migrants
compared to other populations, the expected prevalence of the disease
in this group is 1.3–2.4% [14]. This is slightly lower than a 2015 study
in which the prevalence of Chagas disease in Latin American migrants
living in Europe was estimated at 4.2% [5]. We believe this is due the
UK having a lower proportion of people from the countries with higher
Chagas disease prevalence, Bolivia, Honduras, El Salvador and Para-
guay than other European countries. Based on the estimates of Basile
et al. [3], there is 99% under-diagnosis of CD in the UK. Furthermore,
there has been a surge in Latin American migration to the UK. There
were an estimated 145,500 Latin Americans living in London in 2011, a
four-fold increase since 2001, the main nationalities being Brazilian,
Colombian, Ecuadorian, Peruvian and Bolivian. Most CD in Europe is
found amongst Bolivians [15–19].
Since the global economic recession, increasing numbers of Latin
American migrants have arrived in the UK from Spain. Latin Americans
in London have up to 85% employment rates, but a large number do not
access public services and a fifth have never been to a GP. Access to
testing and care of T. cruzi infection is therefore a problem [7]. Latin
Americans in London often work in manual/low-paid jobs and are not
entitled to or do not claim sick pay. For this reason, attendance at clinic
appointments may be difficult or impossible for them. Healthcare
providers need to be aware of the magnitude of this problem, in order
to access community groups and reach out to migrant communities.
Disseminating information about testing and NHS services amongst this
high-prevalence group would be an important public health interven-
tion.
4.1. Blood and organ donation
Screening of CD in blood-banks has already been implemented in
many European countries, such as Spain, Italy and Switzerland [4].
England was the first non-endemic country to introduce blood and
organ screening for T. cruzi and implementing a programme of selective
screening of high-risk individuals for antibodies has been successful
[20]. Since the introduction of screening for T. cruzi infection in 1998, a
total of 38,585 donors have been screened and only three positive cases
identified. As well as minimising the risk of transmission, this screening
process has a major benefit in reducing the loss of donors [20]. Prior to
1998, guidance suggested permanent deferral of at-risk individuals
from blood donation. The Joint United Kingdom Blood Transfusion
Services Professional Advisory Committee (JPAC) has implemented
screening of at-risk blood products since 1999 [4].
Organ transplantation screening is recommended, but it is unclear
whether it is universally applied [4]. The EU directive on solid organ
transplantation does not specifically mention CD. National transplant
organisations from Italy, Spain and the UK have sections on how to
control T. cruzi transmission. According to the UK Department of
Health's Advisory Committee on the Safety of Blood, Tissue and Organs
(SaBTO) the patient assessment form includes a risk assessment for
Chagas and subsequent serological testing [4].
4.2. Antenatal and congenital screening
When it comes to antenatal screening for CD in pregnant women
Table 2
Kuschnir classification for patients with cardiac symptoms.
ECG Left Ventricular Size CHF Grade Patients with cardiac symptoms N = 21
Normal Normal None 0 7 (33%)
Abnormal Normal None I 8 (37%) (includes one patient with normal ECG but abnormal 24 h tape)
Abnormal Enlarged None II 2 (10%) (based on echocardiogram)
NA Enlarged Present III 2 (10%)
* There were no results available for 2 patients who had been lost to follow up.
Table 3
Rezende classification for patients with gastrointestinal symptoms.
Oesophageal Diameter Gross anatomy Barium Swallow Study Stage Patients with GI symptoms
N = 16
Normal Normal No retention 0 12(75%)
Normal Tertiary contractions present Small barium retention in lower oesophagus I 2 (13%)
Mild to moderate dilatation Greater number of tertiary contractions Barium retention into mid-third of the oesophagus II 0
Moderate to severe dilatation Normal longitudinal axis maintained Significant barium retention III 1 (6%)
Severe dilatation Longitudinal axis deviated IV 0
*One patient was lost to follow up.
Fig. 2. IFAT titre distribution and positive PCR results.
*Number of positive PCR results at specified dilution.
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coming from endemic countries, this has also been shown to be cost-
effective, but its implementation is still limited [21].
The Public Health England Migrant Health Guide states that health-
care practitioners should be aware of the risks of infectious and chronic
disease in migrant groups. Serology should be requested if there is
clinical suspicion of T. cruzi infection. Groups of particular concern
include pregnant women and the infants of seropositive mothers [22].
The CD pooled prevalence rate among pregnant Latin American
women living in Europe is 6.5% [23] with a transmission rate to
newborns of 7.3% [24]. The prevalence of CD in pregnant Latin
American women in the UK is not known, but thought to be similar to
those European figures.
At present, routine antenatal screening for CD of at-risk mothers is
not performed and most children who do become infected will follow
an asymptomatic clinical course so remain undetected. Yet newborns
with acute CD can be treated and cured easily. Furthermore, up to
30%–40% of vertically infected children will suffer cardiac, neurolo-
gical and/or gastrointestinal disease, up to 5–15 years after infection
[1]. Whilst treating patients with CD with anti parasitic treatment
during the chronic phase has still not been clearly proven substantially
to reduce the long-term complications related to the disease [18],
treatment of infants within the first year of life results in almost 100%
cure [25].
Even though it is estimated that about 3000 women per year from
CD endemic areas receive maternity care in England, it seems that less
than 6% of these women were tested in 2016 [26]. Despite the advice in
the Migrant Health Guide, and in contrast to the situation of blood
transfusion screening which is governed by law, in the UK there is
currently no legislation and no targeted antenatal screening for diag-
nosis and treatment of vertically infected neonates—an intervention
recommended by WHO because of its high treatment efficacy [27].
Screening programmes for Latin American migrants in antenatal care
units and primary care centres in France, Germany, Italy, Switzerland
and Spain have been shown to be cost-effective [28].
We strongly advocate a central directive to require those providing
antenatal care to offer serological screening to pregnant women in at-
risk groups. The T. cruzi antibody test is cheap and is available via the
Public Health England Parasitology Reference Laboratory. Controlling
vertical transmission of T. cruzi has been shown to be clinically and cost
effective [21].
4.3. Screening of all asymptomatic individuals
Screening of asymptomatic individuals with latent CD has not yet
been implemented, but recent cost-effectiveness studies suggest that
screening and treating T. cruzi-seropositive individuals and following
them up in the long term is a cost-effective strategy [28].
5. Future directions and unanswered questions
5.1. Treatment of the indeterminate phase
There are a number of unanswered questions relating to treatment
of CD, not least which groups would benefit most from antiparasitic
drug therapy, as there is variable uptake by our asymptomatic patients.
The BENEFIT trial was the first large randomised controlled trial in-
volving patients with CD, and examined whether trypanocidal therapy
is efficacious in patients with early Chagas heart disease. The results
showed no difference in cardiac deterioration in the treatment group
compared to the placebo group [29]. There is no such trial for patients
who have yet to develop CD-related complications, and most of our
patients at HTD are in the indeterminate phase. Despite the lack of
randomised controlled trials for patients in that phase, current data
from smaller studies suggest some marginal beneficial effect of treat-
ment of patients in the chronic phase [30]. Our aim at HTD is therefore
to detect infection, offer antiparasitic drugs where appropriate and refer
those with complications to specialist cardiac or gastrointestinal ser-
vices before they reach an advanced stage of disease.
5.2. Co-infection with HIV and other immunosuppressed hosts
Concurrent infection with HIV can result in reactivation of asymp-
tomatic CD [31] with individuals with CD4 T-cell counts below
200 cells/uL being at highest risk. Treatment must be considered in co-
infected patients, hence serological testing is recommended [32,33].
Nonetheless, routine testing for T. cruzi infection in at-risk HIV positive
patients has not been implemented in all centres in the UK.
The risk of reactivation is well established in solid organ trans-
plantation. Case reports have been published regarding reactivation of
CD with patients suffering from cancer or autoimmune diseases.
However, the evidence is scarce and consensus guidelines for the
management of these patients would be welcomed [34–36].
5.3. Chagas disease in travellers
So far, we have not identified any cases of T. cruzi infection in
travellers to endemic areas. In Latin America, acai pulp and sugarcane
juice have been associated with CD outbreaks [37]. This form of
transmission is the one that potentially puts more travellers at risk. To
minimise the risk of travel-acquired disease, we also suggest that clin-
icians and travel health specialists provide information regarding CD to
those planning to travel to endemic areas, especially Bolivia and that
clinicians include the differential diagnosis of CD in all migrants from
and travellers to endemic areas, especially countries bordering the Gran
Chaco region (Bolivia, Paraguay, Argentina) where there is significant
ongoing transmission [38].
6. Conclusions
CD is an emerging, under-detected problem among Latin American
migrants in the United Kingdom and there is a need to establish prio-
rities to address the issue. We consider the following to be urgently
required:
i. Implementation of antenatal screening for pregnant women from
Latin America, particularly those from Bolivia. Women born in, or
who have lived in, areas endemic for CD, or whose mothers were
born in or lived in such areas, should be offered ante-natal ser-
ological screening.
ii. Implementation of post-natal monitoring of infants born to infected
mothers, with treatment given if the child is found to be para-
sitaemic. Infants born to seropositive mothers should be closely
monitored, including testing by PCR and microscopy at delivery
and again at 6 weeks of age; if those tests are negative, repeat
serology should be performed at 9 months of age
ii. To raise awareness of the disease among clinicians and in maternity
clinics.
iv. Testing of Latin American migrants should be performed prior to
undergoing immunosuppression and those found positive mon-
itored for evidence of reactivation.
v. Offering screening for CD to HIV-positive patients of Latin-
American origin or whose mother was born in an endemic area.
vi. Active case-detection from sentinel seropositive cases and in-
stituting treatment.
vii. To assess the true epidemiological status of CD in the United
Kingdom through surveillance (prevalence) studies.
vii. To set up an outreach programme to unearth undiagnosed cases
among the Latin American migrant population, including strategies
to reach the illegal migrants.
vii. A complete medical evaluation for those found to be seropositive,
with referral to a tertiary centre for assessment and consideration of
anti-parasitic treatment.
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In summary, the Hospital for Tropical Diseases has specialist ex-
pertise in Chagas disease and is part of University College London
Hospitals, a tertiary care centre incorporating advanced specialist car-
diac and gastroenterology services and the Public Health England
National Parasitology Reference Laboratory. Thus there is already ap-
propriate provision of specialist services to look after patients with CD.
The greater challenge is uptake of testing for this condition and access
to care for those infected, as recommended in the Migrant Health
Guide, but regrettably far from actioned. This situation requires urgent
attention because of the risk of ongoing transmission and silent infec-
tion.
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